Silicon-based agent mitigates fatty liver formation in a CDAHFD60-induced MASH mouse model by enhancing hepatic function.

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disorder marked by hepatic inflammation and injury caused by excessive fat accumulation unrelated to alcohol consumption. Its global.preva lence is increasing with obesity and metabolic syndrome and even at the simple steatosis stage, the risks of atherosclerosis, myocardial infarction, and stroke are elevated. Persistent MASH can advance to cirrhosis and hepatocellular carcinoma, underscoring the urgent need for effective therapies. Because oxidative stress drives MASH progression, antioxidants are considered promising interventions. Silicon (Si)-based agent acts as antioxidants that continuously generate molecular hydrogen through reaction with water, a known reactive oxygen species scavenger. Oral Si-based agent has shown benefits in oxidative stress-related disorders, including ulcerative colitis, Parkinson's disease, and intestinal ischemia-reperfusion injury. Here, we investigated whether Si-based agent exerts therapeutic effects on MASH using a choline-deficient, l-amino acid-defined, high-fat diet (CDAHFD60)-induced MASH mouse model. The Si-based agent was mixed at 2.5% into the CDAHFD60 and administered to mice for 12 weeks. Although no apparent macroscopic differences in fatty liver were observed, Si-based agent-treatment reduced hepatic lipid droplet accumulation by preventing MASH-associated bile dysfunction. Additionally, although the MASH models exhibited hypolipidemia and weight loss, Si-based agent-treatment alleviated hypolipidemia and suppressed weight loss. Furthermore, the Si-based agent attenuated systemic oxidative stress in the MASH mouse model. Overall, Si-based agent improved hepatic and systemic lipid metabolism, exerted systemic antioxidant effects, highlighting its therapeutic potential for MASH.